PharmiWeb Today Story
ConserV Bioscience Limited ("ConserV"), a clinical-stage biotechnology company focused on developing vaccines that protect against endemic and emergent infectious diseases, and eTheRNA immunotherapies NV ("eTheRNA"), a clinical-stage immunotherapy company focused on mRNA antigen delivery and immunostimulation using its ground-breaking TriMix technology, have agreed to collaborate on the development of vaccine candidates for infectious diseases. It is anticipated that by combining ConserV's and eTheRNA's technologies, the new vaccines will induce potent immune responses to protect against highly mutagenic viruses.
This collaboration brings together ConserV's expertise in identifying broadly-protective antigens and eTheRNA's TriMix immunostimulatory mRNA technology and novel lipid nanoparticle ("LNP") encapsulation technologies. Initially, the collaboration will focus on development and evaluation of mRNA vaccine formulations against human immunodeficiency virus (HIV), with the objective of identifying a lead formulation to move forward to clinical development. The collaboration may also develop other mRNA vaccine formulations based upon ConserV's antigen portfolio.
ConserV's candidate antigens include conserved regions from both internal and external viral proteins containing clusters of reactive T-cell epitopes for multiple human leukocyte antigens (HLAs). eTheRNA's TriMix contains three mRNA molecules (caTLR4, CD40L and CD70) that combined work to produce a potent, durable T-cell-mediated immune response. Also, eTheRNA has developed proprie…
Read More...
Articles
Clinical trials in the post Brexit Europe
27-Aug-2020
Preventative medicine
26-Aug-2020
Events
-
asiaPLX 1 Singapore Marketplace for Pharma Busines…
21-Feb-2022 - 22-Feb-2022 -
2nd Euro Diabetes and Endocrinology Congress
06-Dec-2021 - 07-Dec-2021 -
2nd Asian Public Mental Health Congress
29-Nov-2021 - 30-Nov-2021 -
Infectious and Chronic Diseases Congress
22-Nov-2021 - 23-Nov-2021 -
Introduction to Clinical Research
17-Nov-2021 - 17-Nov-2021 -
Reuters Events' Total Health 2021
16-Nov-2021 - 17-Nov-2021
News
-
Ridgeback Biotherapeutics and Merck Announce Preli…
06-Mar-2021 -
Glancy Prongay & Murray LLP, a Leading Securities…
06-Mar-2021 -
Sensient Publishes Its Sixth Annual Sustainability…
05-Mar-2021 -
Glancy Prongay & Murray LLP, a Leading Securities…
05-Mar-2021 -
CA Healthcare Acquisition Corp. Announces the Sepa…
05-Mar-2021 -
Farm Animal Drugs Market In-Depth Analysis, Growth…
05-Mar-2021